CN109311974A - 抗人白细胞介素-17a单克隆抗体、其制备方法和应用 - Google Patents
抗人白细胞介素-17a单克隆抗体、其制备方法和应用 Download PDFInfo
- Publication number
- CN109311974A CN109311974A CN201780033670.5A CN201780033670A CN109311974A CN 109311974 A CN109311974 A CN 109311974A CN 201780033670 A CN201780033670 A CN 201780033670A CN 109311974 A CN109311974 A CN 109311974A
- Authority
- CN
- China
- Prior art keywords
- human
- monoclonal antibody
- seq
- amino acid
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
- C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Physics & Mathematics (AREA)
Abstract
提供了一种抗人IL‑17A单克隆抗体、其制备方法和应用。该抗人IL‑17A单克隆抗体能够特异性与人IL‑17A结合,具有良好的抑制IL‑17A诱导的各种细胞系分泌炎性细胞因子如IL‑6等的效果,可应用于制备治疗免疫介导的炎症反应的疾病的药物。
Description
PCT国内申请,说明书已公开。
Claims (15)
- PCT国内申请,权利要求书已公开。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610405511.0A CN107488227A (zh) | 2016-06-12 | 2016-06-12 | 抗人白细胞介素‑17a单克隆抗体、其制备方法和应用 |
CN2016104055110 | 2016-06-12 | ||
PCT/CN2017/087733 WO2017215524A1 (zh) | 2016-06-12 | 2017-06-09 | 抗人白细胞介素-17a单克隆抗体、其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109311974A true CN109311974A (zh) | 2019-02-05 |
CN109311974B CN109311974B (zh) | 2021-07-09 |
Family
ID=60642645
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610405511.0A Pending CN107488227A (zh) | 2016-06-12 | 2016-06-12 | 抗人白细胞介素‑17a单克隆抗体、其制备方法和应用 |
CN201780033670.5A Active CN109311974B (zh) | 2016-06-12 | 2017-06-09 | 抗人白细胞介素-17a单克隆抗体、其制备方法和应用 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610405511.0A Pending CN107488227A (zh) | 2016-06-12 | 2016-06-12 | 抗人白细胞介素‑17a单克隆抗体、其制备方法和应用 |
Country Status (5)
Country | Link |
---|---|
US (1) | US10738112B2 (zh) |
EP (1) | EP3470427A4 (zh) |
JP (1) | JP6883591B2 (zh) |
CN (2) | CN107488227A (zh) |
WO (1) | WO2017215524A1 (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112250764A (zh) * | 2020-10-22 | 2021-01-22 | 深圳市康瑞克生物科技有限责任公司 | 一种抗白细胞介素17a的单克隆抗体、其编码基因及应用 |
CN113817058A (zh) * | 2021-09-30 | 2021-12-21 | 港科鹏禾生物(苏州)有限公司 | 一种抗人il-17rc的单克隆抗体及其应用 |
CN114920838A (zh) * | 2022-03-25 | 2022-08-19 | 南京融捷康生物科技有限公司 | 一种抗il-17a的单域抗体及其用途 |
WO2023083243A1 (zh) * | 2021-11-11 | 2023-05-19 | 三生国健药业(上海)股份有限公司 | 一种抗il-17/vegf双功能融合蛋白及其用途 |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108640991B (zh) * | 2018-05-17 | 2019-09-27 | 江苏荃信生物医药有限公司 | 抗人白介素17a单克隆抗体及其应用 |
CN110551215A (zh) * | 2018-05-30 | 2019-12-10 | 中山康方生物医药有限公司 | 抗白细胞介素-17a抗体、其药物组合物及其用途 |
EP3689907A1 (en) * | 2019-01-31 | 2020-08-05 | Numab Therapeutics AG | Antibodies targeting il-17a and methods of use thereof |
SG11202107995SA (en) * | 2019-01-31 | 2021-08-30 | Numab Therapeutics AG | Multispecific antibodies having specificity for tnfa and il-17a, antibodies targeting il-17a, and methods of use thereof |
CN110124030A (zh) * | 2019-06-10 | 2019-08-16 | 通化东宝生物科技有限公司 | 一种苏金单抗注射液及其制备方法 |
WO2021018191A1 (zh) * | 2019-07-30 | 2021-02-04 | 江苏恒瑞医药股份有限公司 | Il-17拮抗剂治疗自身免疫疾病的方法 |
CN110585430B (zh) * | 2019-09-29 | 2023-09-08 | 华博生物医药技术(上海)有限公司 | 一种人源化抗人il-17a单克隆抗体的药物组合物 |
CN111647624A (zh) * | 2020-06-10 | 2020-09-11 | 成都和同易创生物科技有限公司 | Tsab人源单克隆抗体重组载体、重组抗体及其制备方法 |
CN112142841B (zh) * | 2020-09-27 | 2022-03-22 | 江苏荃信生物医药股份有限公司 | 一种新的抗人il-17a单克隆抗体、包含其的试剂盒及其检测方法 |
CN112390890B (zh) * | 2020-11-06 | 2022-06-24 | 江苏荃信生物医药股份有限公司 | 一种定量检测血清中抗人白介素17单克隆抗体含量的酶联免疫分析方法 |
CN113896793B (zh) * | 2021-09-30 | 2023-05-26 | 港科鹏禾生物(苏州)有限公司 | 一种抗人il-17rc的单克隆抗体及其应用 |
CN115806615B (zh) * | 2022-07-22 | 2023-07-14 | 深圳贝蒂斯生物科技有限公司 | 抗体和间充质干细胞外泌体制备方法以及联合治疗疾病的用途 |
CN115819579B (zh) * | 2022-11-10 | 2023-11-07 | 浙江大学 | 全人源抗白介素17A单链抗体No.34及应用 |
CN117866902A (zh) * | 2024-03-12 | 2024-04-12 | 北京贝来生物科技有限公司 | 具有抗il-17a活性的基因修饰干细胞及其制备方法以及药物组合物 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007106769A2 (en) * | 2006-03-10 | 2007-09-20 | Zymogenetics, Inc. | Antibodies that bind both il-17a and il-17f and methods of using the same |
WO2008134659A2 (en) * | 2007-04-27 | 2008-11-06 | Zymogenetics, Inc. | Antagonists to il-17a, il-17f, and il-23p19 and methods of use |
WO2009136286A9 (en) * | 2008-05-05 | 2010-04-22 | Novimmune Sa | Anti-il 17a/il-17f cross-reactive antibodies and methods of use thereof |
CN105073775A (zh) * | 2013-02-08 | 2015-11-18 | 诺华股份有限公司 | 抗-il-17a抗体及其在治疗自身免疫性和炎性病症中的用途 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0417487D0 (en) * | 2004-08-05 | 2004-09-08 | Novartis Ag | Organic compound |
SI2481753T1 (en) * | 2005-12-13 | 2018-06-29 | Eli Lilly And Company | Anti-IL-17 antibodies |
TW200815469A (en) * | 2006-06-23 | 2008-04-01 | Astrazeneca Ab | Compounds |
GB0612928D0 (en) * | 2006-06-29 | 2006-08-09 | Ucb Sa | Biological products |
US7886449B2 (en) * | 2007-02-20 | 2011-02-15 | Electro Scientific Industries, Inc. | Flexure guide bearing for short stroke stage |
EP2810652A3 (en) * | 2009-03-05 | 2015-03-11 | AbbVie Inc. | IL-17 binding proteins |
RU2595385C2 (ru) * | 2010-08-05 | 2016-08-27 | Анаптисбайо, Инк. | Антитела, направленные против il-17 |
WO2014161570A1 (en) * | 2013-04-03 | 2014-10-09 | Roche Glycart Ag | Antibodies against human il17 and uses thereof |
HUE052184T2 (hu) * | 2013-11-18 | 2021-12-28 | Shanghai hengrui pharmaceutical co ltd | IL-17A kötõanyag és felhasználásai |
RU2577228C2 (ru) * | 2014-03-14 | 2016-03-10 | Закрытое Акционерное Общество "Биокад" | Анти-il-17-антитела, способ их получения и способ применения |
-
2016
- 2016-06-12 CN CN201610405511.0A patent/CN107488227A/zh active Pending
-
2017
- 2017-06-09 CN CN201780033670.5A patent/CN109311974B/zh active Active
- 2017-06-09 WO PCT/CN2017/087733 patent/WO2017215524A1/zh unknown
- 2017-06-09 JP JP2018562242A patent/JP6883591B2/ja active Active
- 2017-06-09 EP EP17812635.5A patent/EP3470427A4/en not_active Withdrawn
- 2017-06-09 US US16/309,072 patent/US10738112B2/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007106769A2 (en) * | 2006-03-10 | 2007-09-20 | Zymogenetics, Inc. | Antibodies that bind both il-17a and il-17f and methods of using the same |
WO2008134659A2 (en) * | 2007-04-27 | 2008-11-06 | Zymogenetics, Inc. | Antagonists to il-17a, il-17f, and il-23p19 and methods of use |
WO2009136286A9 (en) * | 2008-05-05 | 2010-04-22 | Novimmune Sa | Anti-il 17a/il-17f cross-reactive antibodies and methods of use thereof |
CN105073775A (zh) * | 2013-02-08 | 2015-11-18 | 诺华股份有限公司 | 抗-il-17a抗体及其在治疗自身免疫性和炎性病症中的用途 |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112250764A (zh) * | 2020-10-22 | 2021-01-22 | 深圳市康瑞克生物科技有限责任公司 | 一种抗白细胞介素17a的单克隆抗体、其编码基因及应用 |
CN113817058A (zh) * | 2021-09-30 | 2021-12-21 | 港科鹏禾生物(苏州)有限公司 | 一种抗人il-17rc的单克隆抗体及其应用 |
CN113817058B (zh) * | 2021-09-30 | 2023-05-26 | 港科鹏禾生物(苏州)有限公司 | 一种抗人il-17rc的单克隆抗体及其应用 |
WO2023083243A1 (zh) * | 2021-11-11 | 2023-05-19 | 三生国健药业(上海)股份有限公司 | 一种抗il-17/vegf双功能融合蛋白及其用途 |
CN114920838A (zh) * | 2022-03-25 | 2022-08-19 | 南京融捷康生物科技有限公司 | 一种抗il-17a的单域抗体及其用途 |
CN114920838B (zh) * | 2022-03-25 | 2023-11-24 | 南京融捷康生物科技有限公司 | 一种抗il-17a的单域抗体及其用途 |
Also Published As
Publication number | Publication date |
---|---|
US20190161544A1 (en) | 2019-05-30 |
JP6883591B2 (ja) | 2021-06-09 |
WO2017215524A1 (zh) | 2017-12-21 |
JP2019525730A (ja) | 2019-09-12 |
EP3470427A4 (en) | 2020-03-04 |
CN109311974B (zh) | 2021-07-09 |
US10738112B2 (en) | 2020-08-11 |
EP3470427A1 (en) | 2019-04-17 |
CN107488227A (zh) | 2017-12-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109311974A (zh) | 抗人白细胞介素-17a单克隆抗体、其制备方法和应用 | |
CN111171150B (zh) | 抗人tslp抗体及其用途 | |
KR100852523B1 (ko) | Il-17 길항질 항체 | |
CN104231081B (zh) | 能结合胸腺基质淋巴细胞生成素的抗原结合蛋白 | |
CN108409860B (zh) | 抗人白细胞介素-4受体α单克隆抗体、其制备方法和应用 | |
WO2013165894A2 (en) | St2l antagonists and methods of use | |
CN102782148A (zh) | 与多种cc趋化因子结合的抗因子抗体 | |
EP2417161B1 (en) | Antibodies against il-17br | |
CN106336459B (zh) | 抗人白细胞介素-17a单克隆抗体、其制备方法和应用 | |
AU2024200493A1 (en) | ANTI-IL-23p19 ANTIBODY AND USE THEREOF | |
CN112513090A (zh) | 结合人il-4r的抗体、其抗原结合片段及其医药用途 | |
CA2913118A1 (en) | Anti-tnf-.alpha./cxcl10 double-targeting antibody and use thereof | |
CN109942706A (zh) | 结合人il-5的单克隆抗体、其制备方法和用途 | |
CN112480254B (zh) | 抗人白细胞介素-33受体的抗体及其制备方法和应用 | |
CN113234157B (zh) | 亲和力成熟的人源化抗人il-33单克隆抗体及其应用 | |
EP3683234A1 (en) | Il-6r antibody and antigen binding fragment thereof and medical use | |
KR20230004576A (ko) | 항인간 인터루킨-4수용체 α항체의 제조방법과 용도 | |
CN114437212B (zh) | 抗人胸腺基质淋巴细胞生成素抗体及其制备方法和应用 | |
WO2020102935A1 (en) | Anti-il-25 antibodies and use thereof | |
CN112480252A (zh) | 抗白细胞介素-33抗体及其制备方法和应用 | |
RU2807060C1 (ru) | Антитело к альфа-рецептору интерлейкина-4 человека, способ его получения и его применение | |
CN116217725B (zh) | 一种抗tslp单克隆抗体的纯化方法 | |
CN115433275A (zh) | 抗胸腺基质淋巴细胞生成素(tslp)抗体及其用途 | |
Chen et al. | Generation and characterization of a humanized anti-IL-17A rabbit monoclonal antibody | |
CN110922483A (zh) | 抗ccr5抗体及其在治疗肿瘤中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |